Does Switching to Another Antipsychotic in Patients With Clozapine-Associated Granulocytopenia Solve the Problem? Case Series of 18 Patients

COŞAR B., TANER M. E., Eser H. Y., ALTINÖZ A. E., Tarhan R.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.31, no.2, pp.169-173, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31 Issue: 2
  • Publication Date: 2011
  • Doi Number: 10.1097/jcp.0b013e31820e3d9d
  • Journal Name: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.169-173
  • Keywords: clozapine, agranulocytosis, prolongation, schizophrenia, olanzapine, quetiapine, antipsychotic, OLANZAPINE-INDUCED NEUTROPENIA, RISPERIDONE-INDUCED LEUKOPENIA, INDUCED AGRANULOCYTOSIS, REVERSIBLE NEUTROPENIA, PROLONGATION, SAFE
  • Gazi University Affiliated: Yes

Abstract

Clozapine is a well-known drug that is used in treatment-resistant schizophrenia, but granulocytopenia, which may lead to a potentially fatal condition such as agranulocytosis, limit its use. The question about which antipsychotic should be used after a diagnosis of clozapine-associated granulocytopenia is difficult to answer, because antipsychotics other than clozapine may also have hematologic toxicity, or they may prolong clozapine-associated granulocytopenia. In this study, we aimed to find out the incidence of clozapine-associated granulocytopenia in our treatment sample and discuss suitable antipsychotic drug options in terms of hematologic toxicity, for management of clozapine-associated granulocytopenia.